JPWO2021185878A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021185878A5 JPWO2021185878A5 JP2022555821A JP2022555821A JPWO2021185878A5 JP WO2021185878 A5 JPWO2021185878 A5 JP WO2021185878A5 JP 2022555821 A JP2022555821 A JP 2022555821A JP 2022555821 A JP2022555821 A JP 2022555821A JP WO2021185878 A5 JPWO2021185878 A5 JP WO2021185878A5
- Authority
- JP
- Japan
- Prior art keywords
- disorders
- pharmaceutical composition
- crystalline
- process according
- monohydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- -1 5-ethyl-4-methyl-N-[4-[(2S)morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide monohydrochloric acid Chemical compound 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 18
- 238000000034 method Methods 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 6
- 208000011117 substance-related disease Diseases 0.000 claims 6
- 230000032683 aging Effects 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 4
- 208000028017 Psychotic disease Diseases 0.000 claims 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- XHHXGKRFUPEPFM-OAHLLOKOSA-N 5-ethyl-4-methyl-N-[4-[(2S)-morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide Chemical compound C(C)C1=C(C(=NN1)C(=O)NC1=CC=C(C=C1)[C@H]1CNCCO1)C XHHXGKRFUPEPFM-OAHLLOKOSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 238000001816 cooling Methods 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010002942 Apathy Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010012655 Diabetic complications Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 230000002238 attenuated effect Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000036760 body temperature Effects 0.000 claims 2
- 230000027288 circadian rhythm Effects 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 239000007903 gelatin capsule Substances 0.000 claims 2
- 230000013632 homeostatic process Effects 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 239000011541 reaction mixture Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000007958 sleep Effects 0.000 claims 2
- 230000035882 stress Effects 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- 231100000736 substance abuse Toxicity 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000004821 distillation Methods 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 150000004712 monophosphates Chemical class 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025132332A JP2025166092A (ja) | 2020-03-19 | 2025-08-07 | Ｔａａｒ１アゴニストの塩形態および結晶形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20164069 | 2020-03-19 | ||
| EP20164069.5 | 2020-03-19 | ||
| PCT/EP2021/056749 WO2021185878A1 (en) | 2020-03-19 | 2021-03-17 | Salts and crystalline forms of a taar1 agonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025132332A Division JP2025166092A (ja) | 2020-03-19 | 2025-08-07 | Ｔａａｒ１アゴニストの塩形態および結晶形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023517729A JP2023517729A (ja) | 2023-04-26 |
| JPWO2021185878A5 true JPWO2021185878A5 (https=) | 2024-03-26 |
| JP2023517729A5 JP2023517729A5 (https=) | 2024-03-26 |
Family
ID=69846246
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555821A Pending JP2023517729A (ja) | 2020-03-19 | 2021-03-17 | Ｔａａｒ１アゴニストの塩形態および結晶形態 |
| JP2025132332A Pending JP2025166092A (ja) | 2020-03-19 | 2025-08-07 | Ｔａａｒ１アゴニストの塩形態および結晶形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025132332A Pending JP2025166092A (ja) | 2020-03-19 | 2025-08-07 | Ｔａａｒ１アゴニストの塩形態および結晶形態 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230120311A1 (https=) |
| EP (1) | EP4121428B1 (https=) |
| JP (2) | JP2023517729A (https=) |
| KR (1) | KR20220155575A (https=) |
| CN (1) | CN115279752A (https=) |
| AU (1) | AU2021238632A1 (https=) |
| BR (1) | BR112022016746A2 (https=) |
| CA (1) | CA3166331A1 (https=) |
| ES (1) | ES3044409T3 (https=) |
| IL (1) | IL294301A (https=) |
| MX (1) | MX2022010794A (https=) |
| TW (1) | TWI874616B (https=) |
| WO (1) | WO2021185878A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023323858A1 (en) * | 2022-08-12 | 2024-11-21 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions comprising 5-ethyl-4-methyl- n-[4-[(2 s) morpholin-2-yl]phenyl]-1h-pyrazole-3-carboxamide |
| WO2024222860A1 (zh) * | 2023-04-28 | 2024-10-31 | 江苏豪森药业集团有限公司 | 一种吗啉杂环类化合物的盐及其制备方法和应用 |
| CN117903050B (zh) * | 2024-03-15 | 2024-05-17 | 中国药科大学 | 阿立哌唑共晶及其药物组合物和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| WO2017157873A1 (en) * | 2016-03-17 | 2017-09-21 | F. Hoffmann-La Roche Ag | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
-
2021
- 2021-03-17 EP EP21712158.1A patent/EP4121428B1/en active Active
- 2021-03-17 WO PCT/EP2021/056749 patent/WO2021185878A1/en not_active Ceased
- 2021-03-17 ES ES21712158T patent/ES3044409T3/es active Active
- 2021-03-17 TW TW110109520A patent/TWI874616B/zh active
- 2021-03-17 JP JP2022555821A patent/JP2023517729A/ja active Pending
- 2021-03-17 CN CN202180017438.9A patent/CN115279752A/zh active Pending
- 2021-03-17 AU AU2021238632A patent/AU2021238632A1/en active Pending
- 2021-03-17 BR BR112022016746A patent/BR112022016746A2/pt unknown
- 2021-03-17 MX MX2022010794A patent/MX2022010794A/es unknown
- 2021-03-17 IL IL294301A patent/IL294301A/en unknown
- 2021-03-17 CA CA3166331A patent/CA3166331A1/en active Pending
- 2021-03-17 KR KR1020227031814A patent/KR20220155575A/ko active Pending
-
2022
- 2022-09-16 US US17/946,743 patent/US20230120311A1/en active Pending
-
2025
- 2025-08-07 JP JP2025132332A patent/JP2025166092A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI356051B (en) | New crystalline form vi of agomelatine, a process | |
| CN1189170C (zh) | 噻吩基唑基烷氧基乙胺,它们的制备以及它们作为药物的应用 | |
| CN1582278A (zh) | 多晶型rimonabant,其制备方法及含有它的药物组合物 | |
| CN1575287A (zh) | 乙酰替苯胺衍生物的α型或β型结晶 | |
| CN1612863A (zh) | 氘代的取代的吡唑基－苯磺酰胺以及包含该化合物的药物组合物 | |
| TW202200594A (zh) | 一種glp-1受體激動劑的晶型a及其製備方法 | |
| CN1602304A (zh) | 氘代的取代的二氢呋喃酮以及包含该化合物的药物组合物 | |
| JP2025502497A (ja) | ３－［（ベンゾ［ｄ］［１，３］ジオキソラン－４－イル）オキシ］プロピルアミン塩酸塩およびその光学異性体、結晶、ならびに調製方法 | |
| WO2008061456A1 (en) | The folacin-metformin compound and its manufacture | |
| JP2014051517A (ja) | デフェラシロックス（ｉｃｌ６７０ａ）の多形形態 | |
| CN1443178A (zh) | (r)－n－[5－甲基－8－(4－甲基哌嗪－1－基)－1,2,3,4－四氢－2－萘基]－4－吗啉代苯甲酰胺的新形态 | |
| JP2025531344A (ja) | ２ｈ－ベンゾトリアゾール誘導体、その調製方法及びそれを含有する医薬組成物 | |
| CN1044705C (zh) | (1-苯基-1-杂环基)烷烃衍生物、它们的制备方法及其用途 | |
| JP2026504208A (ja) | ベンゾイソチアゾール化合物、その医薬組成物および用途 | |
| JPWO2021185878A5 (https=) | ||
| WO2016095650A1 (zh) | 盐酸优克那非的多晶型物及其制备方法、组合物和用途 | |
| WO2012126386A1 (zh) | 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物 | |
| TW202245746A (zh) | Ｎ－（（ｒ）－２，３－二羥基丙氧基）—３，４—二氟—２—（２—氟—４—碘—苯基胺基)—苯甲醯胺之基本上純的形式ｉｖ之組合物及其用途 | |
| JP2007536358A (ja) | 抗糖尿病性ロシグリタゾン誘導体の合成 | |
| CN102557979B (zh) | 一种阿戈美拉汀的晶型、其制备方法、用途及药物组合物 | |
| CN102093309B (zh) | 非布司他的晶型及其制备方法 | |
| JP5913293B2 (ja) | 芳香族ブタン−２−オール化合物ならびにその製造および使用 | |
| CN119039301B (zh) | 一种含氮杂环的多环化合物晶型ⅰ的制备方法 | |
| CN1880294A (zh) | 右酮洛芬氨丁三醇的多晶型、其制备方法和包含它的组合物 | |
| WO2010032731A1 (ja) | 結晶態様のベンゾイミダゾール化合物又はその塩 |